Waterhemp powder.
Brand name products often contain multiple ingredients. To read detailed information about each ingredient, click on the link for the individual ingredient shown above.
Below is general information about the effectiveness of the known ingredients contained in the product Waterhemp Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
There is insufficient reliable information available about the effectiveness of hemp agrimony.
Below is general information about the safety of the known ingredients contained in the product Waterhemp Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
LIKELY UNSAFE ...when products containing hepatotoxic pyrrolizidine alkaloid (PA) constituents are used orally. Repeated exposure to low concentrations of hepatotoxic PAs can cause severe veno-occlusive disease. Hepatotoxic PAs might also be carcinogenic and mutagenic (12841,12842). Tell patients not to use hemp agrimony preparations that are not certified and labeled as hepatotoxic PA-free. ...when products containing hepatotoxic PAs are used topically on abraded or broken skin. Absorption of hepatotoxic PAs through broken skin can lead to systemic toxicities (12841). Tell patients not to use topical hemp agrimony preparations that are not certified and labeled as hepatotoxic PA-free. There is insufficient reliable information available about the safety of using topical PA-free hemp agrimony on unbroken skin.
PREGNANCY: LIKELY UNSAFE
when used orally.
Hemp agrimony preparations, containing hepatotoxic pyrrolizidine alkaloid (PA) constituents, might be teratogenic and hepatotoxic (12841,12842). There is insufficient reliable information available about the safety of using hemp agrimony products that do not contain hepatotoxic PAs during pregnancy.
LACTATION: LIKELY UNSAFE
when used orally.
Hepatotoxic pyrrolizidine alkaloid (PA) constituents in hemp agrimony are excreted in milk (12841,12842). There is insufficient reliable information available about the safety of using hemp agrimony products that do not contain hepatotoxic PAs during lactation.
Below is general information about the interactions of the known ingredients contained in the product Waterhemp Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
Hemp agrimony contains hepatotoxic pyrrolizidine alkaloids (PA) which are substrates of cytochrome P450 3A4 (CYP3A4) (12841,12860). Theoretically, drugs that induce CYP3A4 might increase the conversion of PAs to toxic metabolites. Some drugs that induce CYP3A4 include carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), rifampin, rifabutin (Mycobutin), and others.
|
Hemp agrimony contains hepatotoxic pyrrolizidine alkaloids (PA) (12841,12860). Theoretically, using hemp agrimony with hepatotoxic drugs might have additive adverse effects on the liver. Some drugs that can adversely affect the liver include acetaminophen (Tylenol and others), amiodarone (Cordarone), carbamazepine (Tegretol), isoniazid (INH), methotrexate (Rheumatrex), methyldopa (Aldomet), fluconazole (Diflucan), itraconazole (Sporanox), erythromycin (Erythrocin, Ilosone, others), phenytoin (Dilantin), lovastatin (Mevacor), pravastatin (Pravachol), simvastatin (Zocor), and many others.
|
Below is general information about the adverse effects of the known ingredients contained in the product Waterhemp Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General ...Orally, the major concern with hemp agrimony preparations is the hepatotoxic pyrrolizidine alkaloid (PA) content. These constituents are hepatotoxic, pneumotoxic, carcinogenic, and mutagenic (12841,12842). Chronic exposure to other plants containing hepatotoxic PA constituents is associated with veno-occlusive disease (4021,12842). Dietary supplements sold in the US are not required to disclose the amount of PAs they contain (3484); therefore, all oral preparations containing hemp agrimony should be considered potentially unsafe.
Hepatic ...Orally, the major concern with hemp agrimony preparations is the hepatotoxic pyrrolizidine alkaloid (PA) content (12841,12842). Chronic exposure to other plants containing hepatotoxic PA constituents is associated with veno-occlusive disease (4021). Subacute veno-occlusive disease causes vague symptoms with persistent liver enlargement (4021). Symptoms of acute veno-occlusive disease include colicky epigastrium pain, vomiting and diarrhea, and ascites formation within several days. Enlargement and induration of the liver occurs within a few weeks (12842). Dietary supplements sold in the US are not required to disclose the amount of PAs they contain (3484); therefore, all oral preparations containing hemp agrimony should be considered potentially unsafe.